Speaker Profile

Ph.D., Rehnborg Farquhar Professor of Medicine, Stanford University

For ~30 years Christopher Gardner has studied what to consume and to avoid for optimal health, and how best to motivate individuals to achieve healthy dietary behaviors. Some of the dozens of human nutrition intervention trials he has conducted include studies of garlic, omega-3 fats, soy phytoestrogens and antioxidants. Among his most cited studies are the A TO Z (JAMA 2007) and the DIETFITS (JAMA 2018) weight loss diet trials. The DIETFITS trial examined the possibility that a 3-SNP multilocus genotype would predict differential weight loss success on a Healthy-Low-Fat vs. a Healthy-Low-Carb diet among more than 600 overweight and obese adults. His interests in this area of personalized nutrition continue with his participation in the Trans-NIH Consortium: Randomized Controlled Trials of Lifestyle Weight Loss Interventions for Genome-wide Association Studies. He is also working on personalized nutrition explorations with other investigators.

DNA-based Weight Loss Interventions: What Have We Learned?
The 2018 DIETFITS study tested the hypothesis that a 3-SNP genotype pattern would be an effect modifier of weight loss on a healthy low-fat vs. a healthy low-carb diet. The hypothesis was not supported. NIH convened a consortium too look at this question across studies. What have they learned?

 Session Abstract – PMWC 2022 Silicon Valley

  • Fireside Chat with Conrad Vial, Sutter Health and Precision Medicine Practices
    - Conrad Vial, Sutter Health
    - Erika Vial-Monteverdi, RotaCare Clinics
  • Precision Approaches to Chronic Disease
    Session Chair: Jennifer Lovejoy, Seven
    - Noel Mueller, Johns Hopkins
    - Maureen K. O'Connor, ZealCare
    - Sunjya K. Schweig, California Center For Functional Medicine (CCFM)
  • DNA-based Weight Loss Interventions: What Have We Learned?
    Session Chair: Jennifer Lovejoy, Seven
    - George Bray, Pennington Biomedical Research Center
    - Christopher Gardner, Stanford
  • A Scalable, Secure, and Interoperable Platform for Diabetes Detection and Management
    Session Chair: Mike Snyder, Stanford
    - Jessilyn Dunn, Duke
    - Jonathan Long, Stanford
  • Illumina Accelerator Session
    Co-Chairs: Amanda Cashin, Illumina Accelerator & Marc Martin-Casas, Illumina Accelerator
    - Trevor Levin, Convergent
    - Rhidi Tariyal, NextGen Jane
    - Kareem Barghouti, VastBiome